Page last updated: 2024-12-07

l 703606

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L 703606: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID132629
CHEMBL ID24999
SCHEMBL ID15271416
MeSH IDM0206538

Synonyms (32)

Synonym
MLS002172464 ,
smr001254095
l-703,606
gtpl2104
(7r,8r)-7-[di(phenyl)methyl]-n-[(2-iodophenyl)methyl]-1-azabicyclo[2.2.2]octan-8-amine
l703606
l 703606
(cis)-n-(2-iodobenzyl)-2-benzhydrylquinuclidin-3-amine
bdbm50140771
((2r,3r)-2-benzhydryl-1-aza-bicyclo[2.2.2]oct-3-yl)-(2-iodo-benzyl)-amine
CHEMBL24999 ,
(cis)-2-(diphenylmethyl)-n-((2-iodophenyl)methyl)-1-azabicyclo(2.2.2)octan-3-amine
2-(diphenylmethyl)-n-((2-iodophenyl)methyl)-1-azabicyclo(2.2.2)octan-3-amine
144425-84-3
2-(diphenylmethyl)-n-((2-iodophenyl)methyl)-3-quinuclidinamine
l-703606
(i125)l-703606
(2r,3r)-2-benzhydryl-n-[(2-iodophenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine
1-azabicyclo(2.2.2)octan-3-amine, 2-(diphenylmethyl)-n-((2-iodophenyl)methyl)-, cis-
[(2r,3r)-2-benzhydrylquinuclidin-3-yl]-(2-iodobenzyl)amine;oxalic acid;hydrate
cid_25102597
(2r,3r)-2-benzhydryl-n-[(2-iodophenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine;oxalic acid;hydrate
(2r,3r)-2-(diphenylmethyl)-n-[(2-iodanylphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine;ethanedioic acid;hydrate
bdbm79212
(2r,3r)-2-(diphenylmethyl)-n-[(2-iodophenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine;oxalic acid;hydrate
SCHEMBL15271416
DTXSID10162704
MLS-0412840
Q27078408
(2r,3r)-2-benzhydryl-n-(2-iodobenzyl)quinuclidin-3-amine
rel-(2r,3r)-2-benzhydryl-n-(2-iodobenzyl)quinuclidin-3-amine
SDCCGMLS-0412840.P031
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Substance-P receptorHomo sapiens (human)IC50 (µMol)0.00160.00000.09526.8130AID208276
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Substance-P receptorHomo sapiens (human)EC50 (µMol)0.02440.00010.00400.0244AID380505
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (38)

Processvia Protein(s)Taxonomy
aggressive behaviorSubstance-P receptorHomo sapiens (human)
positive regulation of leukocyte migrationSubstance-P receptorHomo sapiens (human)
angiotensin-mediated drinking behaviorSubstance-P receptorHomo sapiens (human)
inflammatory responseSubstance-P receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySubstance-P receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationSubstance-P receptorHomo sapiens (human)
tachykinin receptor signaling pathwaySubstance-P receptorHomo sapiens (human)
long-term memorySubstance-P receptorHomo sapiens (human)
associative learningSubstance-P receptorHomo sapiens (human)
detection of abiotic stimulusSubstance-P receptorHomo sapiens (human)
response to ozoneSubstance-P receptorHomo sapiens (human)
positive regulation of epithelial cell migrationSubstance-P receptorHomo sapiens (human)
response to auditory stimulusSubstance-P receptorHomo sapiens (human)
regulation of smooth muscle cell migrationSubstance-P receptorHomo sapiens (human)
positive regulation of synaptic transmission, cholinergicSubstance-P receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicSubstance-P receptorHomo sapiens (human)
response to estradiolSubstance-P receptorHomo sapiens (human)
response to progesteroneSubstance-P receptorHomo sapiens (human)
response to nicotineSubstance-P receptorHomo sapiens (human)
operant conditioningSubstance-P receptorHomo sapiens (human)
sperm ejaculationSubstance-P receptorHomo sapiens (human)
eating behaviorSubstance-P receptorHomo sapiens (human)
positive regulation of vascular permeabilitySubstance-P receptorHomo sapiens (human)
response to ethanolSubstance-P receptorHomo sapiens (human)
positive regulation of action potentialSubstance-P receptorHomo sapiens (human)
positive regulation of blood pressureSubstance-P receptorHomo sapiens (human)
positive regulation of ossificationSubstance-P receptorHomo sapiens (human)
positive regulation of vasoconstrictionSubstance-P receptorHomo sapiens (human)
positive regulation of hormone secretionSubstance-P receptorHomo sapiens (human)
behavioral response to painSubstance-P receptorHomo sapiens (human)
regulation of smooth muscle cell proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of lymphocyte proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of stress fiber assemblySubstance-P receptorHomo sapiens (human)
response to electrical stimulusSubstance-P receptorHomo sapiens (human)
smooth muscle contraction involved in micturitionSubstance-P receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionSubstance-P receptorHomo sapiens (human)
positive regulation of flagellated sperm motilitySubstance-P receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
tachykinin receptor activitySubstance-P receptorHomo sapiens (human)
protein bindingSubstance-P receptorHomo sapiens (human)
substance P receptor activitySubstance-P receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
plasma membraneSubstance-P receptorHomo sapiens (human)
cell surfaceSubstance-P receptorHomo sapiens (human)
dendriteSubstance-P receptorHomo sapiens (human)
sperm flagellumSubstance-P receptorHomo sapiens (human)
cell bodySubstance-P receptorHomo sapiens (human)
sperm headSubstance-P receptorHomo sapiens (human)
sperm midpieceSubstance-P receptorHomo sapiens (human)
plasma membraneSubstance-P receptorHomo sapiens (human)
sperm midpieceSubstance-P receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID208276Binding affinity against human Tachykinin receptor 1 expressed in astrocytoma UC11MG cells using [125I]- SP radioligand2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
A non-peptide NK1 receptor agonist showing subpicomolar affinity.
AID1628462Intrinsic antimalarial activity against intermediate chloroquine-resistant Plasmodium falciparum 7G8 isolate MRA-154 harboring CRT SVMNT haplotype mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628459Inhibition of CRT K76T mutant in chloroquine/artemisinin-resistant Plasmodium falciparum NHP4773 assessed as reversal of chloroquine resistance by measuring reduction in chloroquine IC50 at 500 nM relative to chloroquine alone2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628457Inhibition of CRT K76T mutant in chloroquine/artemisinin-resistant Plasmodium falciparum ARS272 assessed as reversal of chloroquine resistance by measuring reduction in chloroquine IC50 at 500 nM relative to chloroquine alone2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID208262Inhibition of labeled SP total binding to human Tachykinin receptor 1 expressed in astrocytoma UC11MG cells2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
A non-peptide NK1 receptor agonist showing subpicomolar affinity.
AID1628467Intrinsic antimalarial activity against chloroquine-resistant Plasmodium falciparum NHP4559 harboring CRT K76T mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628465Intrinsic antimalarial activity against chloroquine/artemisinin-resistant Plasmodium falciparum ARS233 harboring CRT K76T mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628460Intrinsic antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 isolate MRA-102 assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628478Cytotoxicity against TAMH assessed as reduction in cell viability by CellTiter-Glo assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628463Intrinsic antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 isolate MRA-159 harboring CRT CVIET haplotype mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628479Cytotoxicity against human AC10 cells assessed as reduction in cell viability by CellTiter-Glo assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628453Inhibition of CRT SVMNT haplotype mutant in intermediate chloroquine-resistant Plasmodium falciparum 7G8 isolate MRA-154 t assessed as reversal of chloroquine resistance by measuring reduction in chloroquine IC50 at 500 nM relative to chloroquine alone2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628484Permeability of compound incubated for 16 hrs at pH 7.4 by PAMPA2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628485Inhibition of CRT CVIET haplotype mutant in Plasmodium falciparum K1 isolate MRA-159 infected in erythrocytes assessed as reversal of chloroquine resistance by measuring reduction in chloroquine IC50 by Hoechst 33342 staining based flow cytometry2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628449Inhibition of CRT CVIET haplotype mutant in Plasmodium falciparum K1 isolate MRA-159 infected in erythrocytes assessed as chloroquine-coumarin probe accumulation at 10 uM after 10 hrs by Hoechst 33342 staining based flow cytometry (Rvb = 35.57 +/- 3.84%)2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628458Inhibition of CRT K76T mutant in chloroquine-resistant Plasmodium falciparum NHP4559 assessed as reversal of chloroquine resistance by measuring reduction in chloroquine IC50 at 500 nM relative to chloroquine alone2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628475Cytotoxicity against TAMH assessed as chloroquine IC50 by measuring reduction in cell viability at 100 nM by CellTiter-Glo assay (Rvb = 85.26 +/- 3.01 uM)2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628481Therapeutic index, ratio of IC50 for human AC10 cells to EC50 for chloroquine-resistant Plasmodium falciparum K1 isolate MRA-159 CRT CVIET haplotype mutant2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628468Intrinsic antimalarial activity against chloroquine/artemisinin-resistant Plasmodium falciparum NHP4773 harboring CRT K76T mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628483Permeability of compound incubated for 6 hrs at pH 7.4 by PAMPA2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628470Resistance index, ratio of chloroquine IC50 for chloroquine-resistant Plasmodium falciparum K1 isolate MRA-159 CRT CVIET haplotype mutant to chloroquine IC50 for chloroquine-sensitive Plasmodium falciparum 3D7 isolate MRA-102 at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628464Intrinsic antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 isolate MRA-156 harboring CRT K76T mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628476Cytotoxicity against TAMH assessed as chloroquine IC50 by measuring reduction in cell viability at 1 uM by CellTiter-Glo assay (Rvb = 85.26 +/- 3.01 uM)2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628482Aqueous kinetic solubility of compound in pH 7.4 solution incubated for 24 hrs2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628461Intrinsic antimalarial activity against chloroquine-sensitive Plasmodium falciparum HB3 isolate MRA-155 assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628455Inhibition of CRT K76T mutant in chloroquine-resistant Plasmodium falciparum Dd2 isolate MRA-156 assessed as reversal of chloroquine resistance by measuring reduction in chloroquine IC50 at 500 nM relative to chloroquine alone2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628451Potentiation of chloroquine-induced antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 isolate MRA-102 assessed as reduction in chloroquine IC50 at 500 nM relative to chloroquine alone2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628454Inhibition of CRT CVIET haplotype mutant in chloroquine-resistant Plasmodium falciparum K1 isolate MRA-159 assessed as reversal of chloroquine resistance by measuring reduction in chloroquine IC50 at 500 nM relative to chloroquine alone2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628456Inhibition of CRT K76T mutant in chloroquine/artemisinin-resistant Plasmodium falciparum ARS233 assessed as reversal of chloroquine resistance by measuring reduction in chloroquine IC50 at 500 nM relative to chloroquine alone2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID380505Displacement of [3H]SR140333 from human recombinant NK1 receptor expressed in CHO cells2006Journal of natural products, Mar, Volume: 69, Issue:3
Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.
AID1628466Intrinsic antimalarial activity against chloroquine/artemisinin-resistant Plasmodium falciparum ARS272 harboring CRT K76T mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628469Resistance index, ratio of chloroquine IC50 for intermediate chloroquine-resistant Plasmodium falciparum 7G8 isolate MRA-154 CRT SVMNT haplotype mutant to chloroquine IC50 for chloroquine-sensitive Plasmodium falciparum 3D7 isolate MRA-102 at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628477Cytotoxicity against TAMH assessed as chloroquine IC50 by measuring reduction in cell viability at 10 uM by CellTiter-Glo assay (Rvb = 85.26 +/- 3.01 uM)2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628452Potentiation of chloroquine-induced antimalarial activity against chloroquine-sensitive Plasmodium falciparum HB3 isolate MRA-155 assessed as reduction in chloroquine IC50 at 500 nM relative to chloroquine alone2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628480Therapeutic index, ratio of IC50 for TAMH to EC50 for chloroquine-resistant Plasmodium falciparum K1 isolate MRA-159 CRT CVIET haplotype mutant2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1346346Human NK1 receptor (Tachykinin receptors)1996The Journal of biological chemistry, Aug-23, Volume: 271, Issue:34
The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (74)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's14 (18.92)18.2507
2000's44 (59.46)29.6817
2010's16 (21.62)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.35 (24.57)
Research Supply Index4.32 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other74 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]